- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for 2017
The Center for Biosimilars recaps the most-read articles of 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the most-read biosimilars articles for the year of 2017.
Number 5: In January, The Center for Biosimilars® provided a look at the marketplace for prospective biosimilars referencing Humira, Enbrel, and Remicade.
Number 4: In December, the FDA approved Mylan and Biocon’s trastuzumab biosimilar, Ogivri, referenced on Herceptin.
Number 3: In January, Pfizer announced that CMS would reimburse for its biosimilar infliximab.
Number 2: In September, the FDA released a heavily redacted Form 483, noting observations that it made when inspecting Celltrion’s manufacturing facility earlier in 2017.
Number 1: In October, the FDA issued a Complete Response Letter for Mylan and Biocon’s pegfilgrastim biosimilar, referenced on Neulasta.
To read all of these articles and more, visit centerforbiosimilars.com.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
